Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Exploring a circulating miRNA signature for PMM2-CDG: Initial insights toward diagnosis, stratification, and monitoring

  • Epifani, Florencia
  • Cabus, Lluc|||0000-0003-3068-4135
  • Nolasco, Gregorio A.
  • Bolasell, Mercè
  • Pérez, Jennifer
  • Alcalá, Adrián
  • Fernández, Patricia
  • Lizano, Esther|||0000-0003-3304-9807
  • Márquez, Gisela
  • Belmonte, Sonia
  • Carbonell-Sala, Sílvia
  • Lagarde, Julien
  • Curado, Joao
  • Hernando Davalillo, Cristina
  • Serrano, Mercedes|||0000-0002-2056-2428
Phosphomannomutase deficiency (PMM2-CDG) is the most common congenital disorder of glycosylation, characterized by variable early-onset neurological (hypotonia, cerebellar syndrome, developmental delay) and multi-organ manifestations. Although several clinical trials are ongoing, current biomarkers lack prognostic or monitoring utility. Emerging transcriptomic studies suggest dysregulated pathways in PMM2-CDG, but miRNAs, key gene expression regulators, remain unexplored. This cross-sectional study aims to investigate a circulating miRNA signature that may distinguish PMM2-CDG patients from unaffected controls, providing an initial framework for future studies on potential predictive and monitoring tools. Differential gene expression analysis was used to identify significant differentially expressed (DE) miRNAs, while machine learning models (LASSO, XGBoost) were applied to create an miRNA predictive signature. Dysregulated miRNA pathways analysis provided insights into affected tissues and cellular mechanisms. An optimized protocol addressing challenges in pediatric blood samples was implemented. miRNA profiles from blood samples of 28 PMM2-CDG patients and 67 unaffected controls were analyzed, identifying six DE miRNAs. Regarding machine learning models, XGBoost achieved the best performance (AUC 0.917). Biological analysis revealed that DE miRNAs influence neurological, endocrinological, immunological, and cellular pathways related to the PMM2-CDG phenotype. Notably, miR-122-5p emerged as a highly predictive marker, indicating liver and neurological involvement. Circulating miRNAs represent a promising, minimally invasive avenue for further investigation. While preliminary evidence of their potential diagnostic utility is provided, additional validation in larger and more diverse populations is required to determine their relevance for clinical stratification or monitoring in PMM2-CDG, contributing to future biomarker-driven personalized medicine efforts in this disease.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Phosphomannomutase deficiency (PMM2-CDG), ataxia and cerebellar assessment

  • Serrano, Mercedes|||0000-0002-2056-2428
  • De Diego, Victor
  • Muchart, Jordi
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Felipe-Rucián, Ana|||0000-0002-5267-1370
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Velázquez Fragua, Ramón
  • Poo, M. Pilar
  • Fons, Carmen|||0000-0001-7227-1350
  • O'Callaghan, Maria del Mar|||0000-0002-1896-1622
  • García-Cazorla, Angels|||0000-0001-9853-688X
  • Boix, Cristina
  • Robles, Bernabé
  • Carratalá, Francisco
  • Girós, Marisa
  • Briones, Paz
  • Gort, Laura|||0000-0003-4746-1034
  • Artuch, R.|||0000-0002-3422-9685
  • Pérez-Cerdá, Celia
  • Jaeken, Jaak
  • Pérez, Belén|||0000-0001-5801-1704
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
Phosphomannomutase deficiency (PMM2-CDG) is the most frequent congenital disorder of glycosylation. The cerebellum is nearly always affected in PMM2-CDG patients, a cerebellar atrophy progression is observed, and cerebellar dysfunction is their main daily functional limitation. Different therapeutic agents are under development, and clinical evaluation of drug candidates will require a standardized score of cerebellar dysfunction. We aim to assess the validity of the International Cooperative Ataxia Rating Scale (ICARS) in children and adolescents with genetically confirmed PMM2-CDG deficiency. We compare ICARS results with the Nijmegen Pediatric CDG Rating Scale (NPCRS), neuroimaging, intelligence quotient (IQ) and molecular data. Our observational study included 13 PMM2-CDG patients and 21 control subjects. Ethical permissions and informed consents were obtained. Three independent child neurologists rated PMM2-CDG patients and control subjects using the ICARS. A single clinician administered the NPCRS. All patients underwent brain MRI, and the relative diameter of the midsagittal vermis was measured. Psychometric evaluations were available in six patients. The Mann-Whitney U test was used to compare ICARS between patients and controls. To evaluate inter-observer agreement in patients' ICARS ratings, intraclass correlation coefficients (ICC) were calculated. ICARS internal consistency was evaluated using Cronbach's alpha. Spearman's rank correlation coefficient test was used to correlate ICARS with NPCRS, midsagittal vermis relative diameter and IQ. ICARS and ICARS subscores differed between patients and controls (p < 0.001). Interobserver agreement of ICARS was "almost perfect" (ICC = 0.99), with a "good" internal reliability (Cronbach's alpha = 0.72). ICARS was significantly correlated with the total NPCRS score (r 0.90, p < 0.001). However, there was no agreement regarding categories of severity. Regarding neuroimaging, inverse correlations between ICARS and midsagittal vermis relative diameter (r -0.85, p = 0.003) and IQ (r -0.94, p = 0.005) were found. Patients bearing p.E93A, p.C241S or p.R162W mutations presented a milder phenotype. ICARS is a reliable instrument for assessment of PMM2-CDG patients, without significant inter-rater variability. Despite our limited sample size, the results show a good correlation between functional cerebellar assessment, IQ and neuroimagingFor the first a correlation between ICARS, neuroimaging and IQ in PMM2-CDG patients has been demonstrated.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG), Evidence for Hypoglycosylation-Driven Channelopathy

  • Izquierdo-Serra, Mercè|||0000-0002-3524-8052
  • Martínez-Monseny, Antonio F.
  • López López, Laura|||0000-0002-8653-6206
  • Carrillo-García, Julia
  • Edo Salvador, Ángel
  • Ortigoza-Escobar, Juan Darío
  • García Campos, Óscar
  • Cancho-Candela, Ramón|||0000-0001-6561-2209
  • Carrasco-Marina, M. Llanos
  • González Gutiérrez-Solana, Luis|||0000-0003-2890-4565
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Muchart, Jordi
  • Montero, Raquel|||0000-0003-0609-5701
  • Artuch, R.|||0000-0002-3422-9685
  • Pérez-Cerdá, Celia
  • Pérez, Belén|||0000-0001-5801-1704
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Fernández-Fernández, José Manuel|||0000-0003-2330-8449
  • Serrano, Mercedes|||0000-0002-2056-2428
Stroke-like episodes (SLE) occur in phosphomannomutase deficiency (PMM2-CDG), and may complicate the course of channelopathies related to Familial Hemiplegic Migraine (FHM) caused by mutations in CACNA1A (encoding Ca2.1 channel). The underlying pathomechanisms are unknown. We analyze clinical variables to detect risk factors for SLE in a series of 43 PMM2-CDG patients. We explore the hypothesis of abnormal Ca2.1 function due to aberrant N -glycosylation as a potential novel pathomechanism of SLE and ataxia in PMM2-CDG by using whole-cell patch-clamp, N -glycosylation blockade and mutagenesis. Nine SLE were identified. Neuroimages showed no signs of stroke. Comparison of characteristics between SLE positive versus negative patients' group showed no differences. Acute and chronic phenotypes of patients with PMM2-CDG or CACNA1A channelopathies show similarities. Hypoglycosylation of both Ca2.1 subunits (α and α) induced gain-of-function effects on channel gating that mirrored those reported for pathogenic CACNA1A mutations linked to FHM and ataxia. Unoccupied N -glycosylation site N283 at α contributes to a gain-of-function by lessening Ca2.1 inactivation. Hypoglycosylation of the αδ subunit also participates in the gain-of-function effect by promoting voltage-dependent opening of the Ca2.1 channel. Ca2.1 hypoglycosylation may cause ataxia and SLEs in PMM2-CDG patients. Aberrant Ca2.1 N -glycosylation as a novel pathomechanism in PMM2-CDG opens new therapeutic possibilities.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A quantitative assessment of the evolution of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG)

  • Serrano, Natalia Lourdes
  • De Diego, Victor
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Martinez Monseny, Antonio F.
  • Velázquez Fragua, Ramón
  • López López, Laura|||0000-0002-8653-6206
  • Felipe-Rucián, Ana|||0000-0002-5267-1370
  • González Gutiérrez-Solana, Luis|||0000-0003-2890-4565
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Serrano, Mercedes|||0000-0002-2056-2428
We aim to delineate the progression of cerebellar syndrome in children with phosphomannomutase-deficiency (PMM2-CDG) using the International Cooperative Ataxia Rating Scale (ICARS). We sought correlation between cerebellar volumetry and clinical situation. We prospectively evaluated PMM2-CDG patients aged from 5 to 18 years through ICARS at two different time points set apart by at least 20 months. We reviewed available MRIs and performed volumetric analysis when it was possible. From the eligible 24, four patients were excluded due to severe mental disability (n = 2) and supratentorial lesions (n = 2). Two different ICARS evaluations separated by more than 20 months were available for 14 patients showing an improvement in the cerebellar syndrome: ICARS1: 35.71 versus ICARS2: 30.07 (p < 0.001). When we considered time, we saw an improvement of 2.64 points in the ICARS per year with an SD of 1.97 points (p < 0.001). The ICARS subscales results improved with time, reaching statistical significance in "Posture and gait" (p < 0.001), "Kinetic functions" (p = 0.04) and "Speech abnormalities" (p = 0.045). We found a negative correlation between the ICARS results and total cerebellar volume (r = -0.9, p = 0.037) in a group of five patients with available volumetric study, meaning that the higher the ICARS score, the more severe was the cerebellar atrophy. Our study shows a stabilization or mild improvement in the cerebellar functions of paediatric PMM2-CDG patients despite cerebellar volume loss. ICARS is a valid scale to quantify the evolution of cerebellar syndrome in PMM2-CDG patients. The availability of ICARS and other reliable and sensitive follow-up tools may prove essential for the evaluation of potential therapies. The online version of this article (10.1186/s13023-017-0707-0) contains supplementary material, which is available to authorized users.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Untangling adaptive functioning of PMM2-CDG across age and its impact on parental stress, a cross-sectional study

  • Epifani, Florencia
  • Pujol Serra, Susana María
  • Llorens, Marta|||0000-0001-8532-0115
  • Balcells, Sol
  • Nolasco, Gregorio
  • Bolasell, Mercè
  • Aguilera-Albesa, Sergio|||0000-0003-3540-1448
  • Cancho Candela, Ramon
  • Cuevas Cervera, José Luis
  • García Sánchez, Verónica
  • García Campos, Óscar
  • Miranda-Herrero, María Concepción
  • Moreno-Lozano, Pedro J.
  • Robles, Bernabé
  • Roldán Aparicio, Susana
  • Velázquez Fragua, Ramón
  • Serrano, Mercedes|||0000-0002-2056-2428
Phosphomannomutase deficiency (PMM2-CDG) leads to cerebellar atrophy with ataxia, dysmetria, and intellectual deficits. Despite advances in therapy, the cognitive and adaptive profile remains unknown. Our study explores the adaptive profile of 37 PMM2-CDG patients, examining its association with parental stress and medical characteristics. Assessment tools included ICARS for the cerebellar syndrome and NPCRS for global disease severity. Behavioral and adaptive evaluation consisted of the Vineland Adaptive Behavior Scale and the Health of the Nation Outcome Scales. Psychopathological screening involved the Child Behavior Checklist and the Symptom Check-List-90-R. Parental stress was evaluated using Parental Stress Index. Results were correlated with clinical features. No significant age or sex differences were found. 'Daily living skills' were notably affected. Patients severely affected exhibited lower adaptive skill values, as did those with lipodystrophy and inverted nipples. Greater severity in motor cerebellar syndrome, behavioral disturbances and the presence of comorbidities such as hyperactivity, autistic features and moderate-to-severe intellectual disability correlated with greater parental stress. Our study found no decline in adaptive abilities. We provide tools to assess adaptive deficits in PMM2-CDG patients, emphasizing the importance of addressing communication, daily living skills, and autonomy, and their impact on parental stress in clinical monitoring and future therapies.